View Older Stories
-
Sarepta (SRPT) could jump 30%+ following positive AdCom on DMD treatment SRP-9001
-
Sarepta (SRPT) gains as Citi initiates at Buy, sees shares outperforming next 2 months
-
Citi Starts Sarepta Therapeutics (SRPT) at Buy; Expects Positive SRP-9001 AdCom
-
Citi opens an upside 90-day catalyst watch on Sarepta Therapeutics (SRPT)
-
Citi Explains Why You Should Buy the Dip in Sarepta Therapeutics (SRPT)
-
Pre-Open Movers 08/25: (OVID) (GPS) (CRM) Higher; (PLCE) (POR) (PANW) Lower (more...)
-
Sarepta Therapeutics (SRPT) Defended at Citi After Shares Drop 12% in 2 Days
-
3 Reasons the Sarepta Therapeutics (SRPT) Deal Looks Favorable - Citi
-
Sarepta Therapeutics (SRPT) PT Raised to $177 at Citi
-
Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug
-
Sarepta Therapeutics (SRPT) Is Heading into a Transformative 2020, PT Cut to $167 at Citi
-
Citi Defends Sarepta Therapeutics (SRPT) As Top Buy
-
Sarepta Therapeutics (SRPT) PT Lowered to $180 at Citi
-
Amarin (AMRN) and Sarepta (SRPT) Added to Citi Top 5 Biotechs List
-
Sarepta Therapeutics (SRPT) PT Lowered to $185 at Citi
-
Sarepta Therapeutics (SRPT) PT Lowered to $190 at Citi
-
Sarepta Therapeutics (SRPT) Update Is A Slight Positive - Citi
-
No Bad News from Sarepta Therapeutics (SRPT) Update is 'Good News' - Citi
-
Sarepta Therapeutics (SRPT) PT Raised to $201 at Citi
-
Sarepta Therapeutics (SRPT) PT Raised to $188 at Citi
-
Citi Starts Sarepta Therapeutics (SRPT) at Buy with $174 PT
-
Pre-Open Movers 07/20: (HPJ) (SHLD) (SRPT) Higher; (PTC) (CHRW) (FMSA) Lower (more...)
-
After-Hours Stock Movers 07/19: (HPJ) (AVA) (SRPT) Higher; (PTC) (CFRX) (CHRW) Lower (more...)
-
Pre-Open Movers 06/29: (STZ) (WATT) (WBA) Higher; (FRED) (RAD) (PIR) Lower (more...)
-
After-Hours Movers 06/28: (GEMP) (PRGS) (NXTD) Higher; (PIR) (BLCM) (DOC) Lower (more...)
-
Pre-Open Stock Movers 09/22: (WCIC) (AVXL) (NVAX) Higher; (MLHR) (JBL) (CPK) Lower (more...)
-
Pre-Open Stock Movers 09/14: (VTAE) (SRPT) (HLF) Higher; (AGIO) (CALD) (CBRL) Lower (more...)
-
Pre-Open Stock Movers 06/09: (ACUR) (CBK) (RADA) Higher; (RH) (INSM) (TMH) Lower (more...)
-
Pre-Open Stock Movers 05/24: (MGN) (XCO) (PLCM) (GPRO) Higher; (SSW) (DSW) (SAGE) (BBY) Lower (more...)
-
Notable Analyst Rating Changes 5/3: (MEP) (RSG) (AXTI) Upgraded; (CYH) (UTX) (SRPT) Downgraded
-
Notable Analyst Rating Changes 5/2: (LLL) (SRPT) (VALE) Upgraded; (ARW) (GRPN) (ASPS) Downgraded
-
Pre-Open Stock Movers 03/22: (LEU) (NQ) (ANF) Higher; (GIII) (MFRM) (AGRO) Lower (more...)
-
Streetinsider.com's Hot Lunchtime Reads 12/18: (MSFT) (FXCM) (BMRN) (TK)
-
Pre-Open Stock Movers 10/06: (PMCS) (STRZA) (DD) Higher; (EXAS) (ILMN) (TCS) Lower (more...)
-
Pre-Open Stock Movers 08/26: (CAM) (ANF) (OSK) (GOOGL) Higher; (VSTM) (WEFT) (CENX) Lower (more...)
-
Market Wrap: Fed Quells June Rate Hike Chatter; Big Banks Settle FX Probe; Sarepta Rises on Eteplirsen Plans
-
Streetinsider.com's Hot Lunchtime Reads 4/1: (GS) (AAPL) (AME) (LL) (UHS)
-
Notable Analyst Rating Changes 2/17: (SRPT) (MU) (CCG) Upgraded; (IMAX) (CVC) (JWN) Downgraded
-
Pre-Open Stock Movers 9/24: (LPCN) (MACK) (ACOR) Higher; (ECTE) (ATOS) (GTI) Lower (more...)
-
Notable Analyst Rating Changes 07/22: (AGN) (RLGY) (FANG) Upgraded; (AMZN) (STI) (MTDR) Downgraded
-
Notable Analyst Rating Changes 05/22: (FB) (BAH) (NBR) Upgraded; (MT) (AEO) (SODA) Downgraded
-
Pre-Open Stock Movers 5/22: (NTLS) (ROYL) (PLCE) (SN) Higher; (WUBA) (WB) (MOV) (SINA) Lower (more...)
-
Notable Analyst Rating Changes 04/22: (HD) (ABX) (SRPT) Upgraded; (CWH) (INXN) (QEP) Downgraded
-
Citi Upgrades Sarepta Therapeutic (SRPT) to Neutral
-
Pre-Open Movers 4/21: (SRPT) (CBEY) (ASTM) Higher; (ATHN) (WLT) (PEIX) Lower (more...)
-
Pre-Open Stock Movers 1/16: (ZOOM) (SRPT) (CEC) Higher; (BBY) (NUS) (C) Lower (more...)
-
Sarepta Therapeutics (SRPT) on Watch as FDA Letter Circulates, Suggesting Wiggle Room for Eteplirsen Accelerated Approval
-
Unusual 11 Mid-Day Movers 01/06: (OXBT) (PPHM) (CTIC) Higher; (BCOV) (SCSS) (CHNR) Lower
-
Notable Analyst Rating Changes 01/06: (SCTY) (BSX) (AIG) Upgraded; (TWTR) (AAPL) (SRPT) Downgraded
-
UPDATE: Citi Downgrades Sarepta Therapeutic (SRPT) to Sell